Clinical Trials
19
Trial Phases
3 Phases
Drug Approvals
0
Drug Approvals
No drug approvals found
This company may not have drug approvals in our database
Clinical Trials
Distribution across different clinical trial phases (18 trials with phase data)• Click on a phase to view related trials
EO4010 in Previously Treated Metastatic Colorectal Carcinoma
- First Posted Date
- 2022-10-21
- Last Posted Date
- 2025-08-22
- Lead Sponsor
- Enterome
- Target Recruit Count
- 25
- Registration Number
- NCT05589597
- Locations
- 🇪🇸
Llavero-Hospital Clínico Universitario, Valencia, Spain
🇺🇸MD Anderson, Houston, Texas, United States
🇫🇷Hôpital Jean Minjoz, Besançon, France
EO2040 in Combination With Nivolumab, for Treatment of Patients With Minimal Residual Disease of Colorectal Cancer
- First Posted Date
- 2022-04-28
- Last Posted Date
- 2025-06-11
- Lead Sponsor
- Enterome
- Target Recruit Count
- 1
- Registration Number
- NCT05350501
- Locations
- 🇺🇸
MD Anderson, Houston, Texas, United States
A Novel Vaccine (EO2463) as Monotherapy and in Combination, for Treatment of Patients With Indolent Non-Hodgkin Lymphoma
- Conditions
- Follicular LymphomaMarginal Zone Lymphoma
- Interventions
- First Posted Date
- 2020-12-16
- Last Posted Date
- 2024-12-13
- Lead Sponsor
- Enterome
- Target Recruit Count
- 60
- Registration Number
- NCT04669171
- Locations
- 🇫🇷
CHU d'Amiens-Picardie - Hopital SUD, Amiens, France
🇺🇸Dana Farber Cancer Institute, Boston, Massachusetts, United States
🇺🇸Mayo Clinic, Rochester, Minnesota, United States
A Novel Therapeutic Vaccine (EO2401) in Metastatic Adrenocortical Carcinoma, or Malignant Pheochromocytoma/Paraganglioma
- Conditions
- Adrenocortical CarcinomaPheochromocytomaParaganglioma
- Interventions
- First Posted Date
- 2019-12-05
- Last Posted Date
- 2024-11-12
- Lead Sponsor
- Enterome
- Target Recruit Count
- 70
- Registration Number
- NCT04187404
- Locations
- 🇺🇸
MD Anderson Cancer Center, Houston, Texas, United States
🇩🇰Rigshospitalet, Copenhagen, Denmark
🇫🇷Chu Lille, Lille, France
First-in-Human, Phase 1b/2a Trial of a Multipeptide Therapeutic Vaccine in Patients With Progressive Glioblastoma
- Conditions
- Glioblastoma, Adult
- Interventions
- Biological: Multiple dose of EO2401
- First Posted Date
- 2019-10-04
- Last Posted Date
- 2024-11-11
- Lead Sponsor
- Enterome
- Target Recruit Count
- 100
- Registration Number
- NCT04116658
- Locations
- 🇺🇸
Dana Farber Cancer Institute, Boston, Massachusetts, United States
🇫🇷Centre Georges François Leclerc, Dijon, France
🇫🇷Hôpital Pitié-Salpétrière, Paris, France
- Prev
- 1
- 2
- Next
News
Gut Microbiome Emerges as Key Factor in Cancer Immunotherapy Response and Resistance
Research demonstrates that gut microbiota significantly influences cancer treatment outcomes, with disrupted gut bacteria associated with resistance to immunotherapies and chemotherapy.